Chemistry:Vantictumab
From HandWiki
Short description: Monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | Frizzled receptor |
| Clinical data | |
| Routes of administration | IV |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6322H9722N1674O1988S46 |
| Molar mass | 142461.81 g·mol−1 |
Vantictumab /vænˈtɪktʊmæb/ is a human IgG2 monoclonal antibody designed for the treatment of cancer.[1]
This drug was developed by OncoMed Pharmaceuticals Inc. in partnership with Bayer.[2] OncoMed was awarded a patent in 2016, which is set to expire in 2029.[3] In April 2017, Bayer terminated its option to license vantictumab.[4]
It inhibits wnt signalling by targeting the frizzled receptors on cancer cells.[5]
Phase I trials have been completed for pancreatic cancer, non-small cell lung cancer, and breast cancer. In 2016 results were reported from a phase 1b clinical trial for triple-negative breast cancer[5][6] and in 2020 for pancreatic cancer.[7]
References
- ↑ "Statement on a nonproprietary name adopted by the USAN Council" (PDF). AMA. 28 Nov 2012. https://download.ama-assn.org/resources/doc/usan/x-pub/vantictumab.pdf?cb=1417489538&retrieve=yes.(registration required)
- ↑ "OncoMed Pre-Announces 2014 Year-End Cash Balance and Provides 2015 Guidance". 12 January 2015. https://globenewswire.com/news-release/2015/01/12/696685/10115034/en/OncoMed-Pre-Announces-2014-Year-End-Cash-Balance-and-Provides-2015-Guidance.html.
- ↑ "Annual Report on Form 10-K". OncoMed Pharmaceuticals, Inc.. http://investor.shareholder.com/oncomed/secfiling.cfm?filingID=1564590-16-14426&CIK=1302573.
- ↑ "BRIEF-Oncomed Pharmaceuticals announces Bayer terminates its option to license vantictumab or ipafricept". Reuters. 10 April 2017. https://www.reuters.com/article/brief-oncomed-pharmaceuticals-announces-idUSASA09I3R.
- ↑ 5.0 5.1 "Finally, targeted therapies for triple-negative breast cancer". Medical Xpress. June 2016. http://medicalxpress.com/news/2016-06-therapies-triple-negative-breast-cancer.html.
- ↑ "Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer". Breast Cancer Research and Treatment 184 (1): 53–62. November 2020. doi:10.1007/s10549-020-05817-w. PMID 32803633.
- ↑ "A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer". Investigational New Drugs 38 (3): 821–830. June 2020. doi:10.1007/s10637-019-00824-1. PMID 31338636.
 |  |
